Ligand Pharmaceuticals has made its second major acquisition in 2024, agreeing a $100 million deal to buy Austria’s Apeiron Biologics and a royalty stream for brain cancer drug Qarziba.

Ligand originated, structured ... “Partnering with Castle Creek is an exciting opportunity to advance an orphan drug-designated gene therapy for a serious unmet medical need through Phase ...

G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

With industry-leading ligand- and structure-based design software, you can quickly generate accurate conformational ensembles, even for complex macrocycles, predict bound ligand poses and binding ...

Our comprehensive suite of ligand design and discovery services integrates cutting-edge computational methodologies with domain-specific expertise, empowering researchers and organizations to ...

Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

A novel protein cage system can control and visualize orientational changes in aromatic side chains upon ligand binding. By inducing coordinated molecular changes, this approach enables precise ...

These modules allow the ProteinReDiff framework to capture intricate protein–ligand interactions, improve the fidelity of ...